Lifecome Biochemistry Co Ltd (002868) - Total Liabilities
Based on the latest financial reports, Lifecome Biochemistry Co Ltd (002868) has total liabilities worth CN¥702.61 Million CNY (≈ $102.81 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lifecome Biochemistry Co Ltd - Total Liabilities Trend (2012–2025)
This chart illustrates how Lifecome Biochemistry Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 002868 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Lifecome Biochemistry Co Ltd Competitors by Total Liabilities
The table below lists competitors of Lifecome Biochemistry Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stendörren Fastigheter AB (publ)
ST:STEF-B
|
Sweden | Skr11.19 Billion |
|
Zhejiang Risun Intelligent Technology Co. Ltd. A
SHG:688215
|
China | CN¥668.20 Million |
|
Regulus Therapeutics Inc
NASDAQ:RGLS
|
USA | $5.80 Million |
|
Beijing Tongyizhong New Material Technology Corp
SHG:688722
|
China | CN¥485.86 Million |
|
Shandong Lubei Chemical Co Ltd
SHG:600727
|
China | CN¥5.68 Billion |
|
Beijing Trust Far Tech
SHE:300231
|
China | CN¥815.28 Million |
|
ForFarmers NV
AS:FFARM
|
Netherlands | €672.00 Million |
|
Insteel Industries Inc
NYSE:IIIN
|
USA | $97.29 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Lifecome Biochemistry Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Lifecome Biochemistry Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 10.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.91 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lifecome Biochemistry Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lifecome Biochemistry Co Ltd (2012–2025)
The table below shows the annual total liabilities of Lifecome Biochemistry Co Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥683.78 Million ≈ $100.06 Million |
-54.90% |
| 2024-12-31 | CN¥1.52 Billion ≈ $221.87 Million |
-2.24% |
| 2023-12-31 | CN¥1.55 Billion ≈ $226.95 Million |
+142.12% |
| 2022-12-31 | CN¥640.56 Million ≈ $93.73 Million |
+19.42% |
| 2021-12-31 | CN¥536.38 Million ≈ $78.49 Million |
+164.80% |
| 2020-12-31 | CN¥202.56 Million ≈ $29.64 Million |
-12.52% |
| 2019-12-31 | CN¥231.55 Million ≈ $33.88 Million |
+273.18% |
| 2018-12-31 | CN¥62.05 Million ≈ $9.08 Million |
+2.45% |
| 2017-12-31 | CN¥60.56 Million ≈ $8.86 Million |
-39.02% |
| 2016-12-31 | CN¥99.32 Million ≈ $14.53 Million |
-35.31% |
| 2015-12-31 | CN¥153.54 Million ≈ $22.47 Million |
-22.93% |
| 2014-12-31 | CN¥199.22 Million ≈ $29.15 Million |
-12.03% |
| 2013-12-31 | CN¥226.45 Million ≈ $33.14 Million |
+5.37% |
| 2012-12-31 | CN¥214.92 Million ≈ $31.45 Million |
-- |
About Lifecome Biochemistry Co Ltd
Lifecome Biochemistry Co.,Ltd. engages in research, development, production, and sales of veterinary drugs in China. It offers probiotics and green microbial functional additives; biopesticides, biofertilizers, and pesticide formulations; and food additives. The company was founded in 2003 and is based in Pucheng, China.